FOXO4-DRI: Senolytic Peptide Mechanism and the p53-FOXO4 Axis
Summary
FOXO4-DRI disrupts the FOXO4–p53 interaction and can induce p53 nuclear exclusion and apoptosis in senescent cells. Baar et al. demonstrated preferential killing in human fibroblast cultures and effects in mouse models. Selectivity depends on the model and conditions; it does not establish that all healthy cells are unaffected or that the peptide is safe in humans.
Cellular Senescence Depends on Context
Cellular senescence involves a stable arrest of cell proliferation and changes in cell signaling. Features and consequences vary by cell type and context; no single marker or survival pathway defines every senescent cell.
Baar et al. studied FOXO4-associated survival in senescent human fibroblasts (PMID 28340339). Their findings do not establish universal upregulation of every anti-apoptotic BCL-2-family protein.
Senescence-associated secretions can affect neighboring cells, but they are not universally harmful. Transient senescent cells supported wound closure in a mouse study (Demaria et al., 2014). These context-dependent roles matter when evaluating senolytic treatment.
The FOXO4–p53 Interaction
Baar et al. (PMID 28340339) identified elevated FOXO4 and FOXO4–p53-associated nuclear foci in senescent human fibroblasts. Their peptide interfered with this interaction, promoted p53 exclusion from the nucleus and triggered cell-intrinsic, caspase-dependent apoptosis. This differs from simply increasing transcription of pro-apoptotic genes.
The Original 46-Residue Construct
The original methods disclose a 46-residue D-isoform sequence and a molecular weight of 5358.2 Da. The full construct includes a HIV-TAT-derived cell-penetrating segment. Its D-retro-inverso design was intended to improve proteolytic resistance; it does not establish a numerical plasma half-life (PMID 28340339).
Selectivity Has Experimental Limits
Senescent IMR90 fibroblasts were more sensitive than matched controls in the original experiments. Expanded healthy-donor human chondrocyte cultures also showed reduced senescence-associated cells, but no improvement in chondrogenic potential (PMID 33996787). These findings do not show that every healthy cell is spared.
In a pulmonary-hypertension model, FOXO4-DRI worsened pulmonary hemodynamics and endothelial-cell loss (PMID 36515093). See the safety evidence for this context-dependent warning.
Preclinical Evidence and Human Trial Status
The literature includes human fibroblast, chondrocyte, keloid and endothelial cell experiments, alongside mouse aging and disease models. The preclinical evidence review separates these model-specific findings from clinical evidence. Our human trial status page records the October 14, 2026 registry and literature searches and their limits.
Frequently Asked Questions
How does FOXO4-DRI induce senescent-cell death?
In the original senescent human fibroblast experiments it disrupted the FOXO4–p53 interaction, promoted nuclear exclusion of p53 and triggered caspase-dependent apoptosis. The preferential response of senescent cells under those conditions is not a universal guarantee of healthy-cell safety.
What is a D-retro-inverso peptide?
This design reverses a peptide sequence and uses D-amino acids to preserve aspects of side-chain orientation while changing susceptibility to proteases. The original FOXO4-DRI construct is 46 residues long including its cell-penetrating segment. This design does not provide a measured human half-life.
Is FOXO4-DRI the same as dasatinib plus quercetin?
No. They are different compounds with different mechanisms and evidence bases. Human trials of dasatinib plus quercetin cannot establish the dose, safety or efficacy of FOXO4-DRI.
What do the mouse results show?
Some aging and injury models reported beneficial outcomes, while a pulmonary-hypertension model reported harm. These model-specific findings do not establish clinical benefit or safety in humans.
Citations
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Brandt RM, Putavet DA, et al.
Cell (2017)
Original human-fibroblast and mouse experiments. Illustrated protocols used three alternate-day 5 mg/kg injections, intravenously in the doxorubicin arm and intraperitoneally in specified aging experiments. Later outcomes are follow-up, not continuous dosing or plasma pharmacokinetics.
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Huang Y, He Y, Makarcyzk MJ, Lin H
Frontiers in Bioengineering and Biotechnology (2021)
Expanded healthy-donor chondrocyte cultures showed reduced senescence-associated cells but no improvement in chondrogenic potential.
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born E, Lipskaia L, Breau M, et al.
Circulation (2023)
FOXO4-DRI worsened pulmonary hemodynamics and endothelial-cell loss in serotonin-transporter-overexpressing mice; other interventions were tested in additional rodent models.
Follow Peptpedia on Google
Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.